| Literature DB >> 25119699 |
Nolonwabo Nontongana1, Timothy Sibanda2, Elvis Ngwenya3, Anthony I Okoh4.
Abstract
Escherichia coli is a widespread bacterium encompassing a variety of strains, ranging from highly pathogenic strains, causing worldwide outbreaks of severe diseases to avirulent, well characterized safe laboratory strains. This study evaluated the prevalence and antibiogram profiles of E. coli pathotypes isolated from the Kat River and Fort Beaufort abstraction water. A total of 171 out of 278 confirmed E. coli isolates were positive for at least one pathogenic determinant and these included enteropathogenic E. coli (6%), enterotoxigenic E. coli (47%), uropathogenic E. coli (2%), neonatal meningitis E. coli (5%), diffusely adherent E. coli (1%) and enterohaemorrhagic E. coli (1%). Interestingly, enteroinvasive and enteroaggregative E. coli were not detected. The phenotypic antibiogram profiles of the isolates revealed that all were resistant to penicillin G, while 98% and 38% of the pathotypes were resistant to ampicillin and trimethoprim-sulphamethoxazole, respectively. About 8% of the isolates were resistant to streptomycin. More than half of the isolates exhibited multiple antibiotic resistance with 44% being resistant to three antibiotics and 8% resistant to four antibiotics. We conclude that the Kat River is a reservoir of potentially virulent antibiotic resistant E. coli strains that can cause serious health risks to humans who drink raw water from this river, or in the case that consumption of treated drinking water coincides with failed drinking water processes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25119699 PMCID: PMC4143858 DOI: 10.3390/ijerph110808213
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Kat River flowing through the Kat River valley.
E. coli target genes and primer sequences used to identify/characterise E. coli pathotypes.
| Target Strains | Target Genes | Primer sequence (5’→3’) | Amplicon Size (bp) | Annealing Temp (ºC) | References |
|---|---|---|---|---|---|
| EHEC |
| F-CAGTTAATGTGGTGGCGAAGG | 348 | 55 | [ |
| EPEC |
| F-TCAATGCAGTTCCGTTATCAGTT | 482 | 54 | [ |
| ETEC |
| F-GCACACGGAGCTCCTCAGTC | 218 | 58 | [ |
| EIEC |
| F-CTC GGC ACG TTT TAA TAG TCTGG | 933 | 53 | [ |
| EAEC |
| F-CACAGGCAACTGAAATAAGTCTGG | 378 | 56 | [ |
| DAEC |
| F-GAACGT TGG TTA ATG TGG GGT AA | 542 | 54 | [ |
| UPEC |
| F-AAC CTGGCTTACGCAACTGTACCC GT | 585 | 58 | [ |
| NMEC |
| F-TGGAACCCGCTCGTAATATAC | 900 | 58 | [ |
Minimal Inhibitory Concentration (MIC) Breakpoints for Enterobacteriaceae. Source: (CLSI [25]).
| Test/Reportgroup | Antimicrobialagent | DiskContent (µg) | Zone Diameter Breakpoints, Nearest Whole mm | MIC Interpretive Standard (µg/mL) | ||||
|---|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | |||
|
| Ampicillin | 10 | ≥17 | 14–16 | ≤13 | ≤6 | 16 | ≥32 |
|
| Gentamycin | 10 | ≥15 | 13–14 | ≤12 | ≤4 | 8 | ≥16 |
|
| Amikacin | 30 | ≥17 | 15–16 | ≤14 | ≤16 | 32 | ≥64 |
|
| Streptomycin | 10 | ≥15 | 12–14 | ≤11 | - | - | - |
|
| Kanamycin | 30 | ≥18 | 14–17 | ≤13 | ≤16 | 32 | ≥64 |
|
| Tetracycline | 30 | ≥15 | 12–14 | ≤11 | ≤4 | 8 | ≥16 |
|
| Ciproflaxacin | 5 | ≥21 | 16–20 | ≤15 | ≤1 | 2 | ≥4 |
|
| Norflaxacin | 10 | ≥17 | 13–16 | ≤12 | ≤4 | 8 | ≥16 |
|
| Trimethoprime-sulfamethoxazole | 1.25/23.75 | ≥16 | 11–15 | ≤10 | ≤2/38 | - | ≥4/76 |
|
| Chloramfenicol | 30 | ≥18 | 13–17 | ≤12 | ≤8 | 16 | ≥32 |
Details of target antibiotic resistance genes.
| Antibacterial Agent | Resistance Gene | Sequence | Amplicon size (bp) | Annealing Temp. (°C) | References |
|---|---|---|---|---|---|
| Streptomycin | aadA1 | (F)TATCCAGCTAAGCGCGAACT | 147 | 58 | [ |
| (R)ATTTGCCGACTACCTTGGTC | |||||
| β-Lactams | Bla | (F)TCGCCTGTGTATTATCTCCC | 198 | 52 | [ |
| (R)CGCAGATAAATCACCACAATG | |||||
| Tetracycline | tetA | (F)CCTCAGCTTCTCAACGCGTG | 402 | 56 | [ |
| (R)GCACCTTGCTGATGACTCTT | |||||
| TMP-SMX | dfrA1 | (F)GGAGTGCCAAAGGTGAACAGC | 721 | 45 | [ |
| (R)GAGGCGAAGTCTTGGGTAAAAAC |
Figure 2E. coli counts from all sampling sites for the month of August, September and October.
Figure 3Gel electrophoresis for the detection of Neonatal meningitis E. coli amplicons. Lane 1: 100 bp ladder; Lane 2: Positive control; Lane 3: Negative control; Lane 4–13: Positive samples.
Figure 4Gel electrophoresis for the detection of Enteropathogenic E. coli amplicons. Lane 1: 100 bp ladder; Lane 2: Negative control; Lane 3: Positive control; Lane 4–13: Positive samples.
Figure 5Gel electrophoresis for the detection of Enterotoxigenic E. coli amplicons. Lane 1: 100 bp ladder; Lane 2: Positive control; Lane 3: Negative control; Lane 4–11: Positive samples.
Figure 6Gel electrophoresis for the detection of Uropathogenic E. coli amplicons. Lane 1: 100 bp ladder; Lane 2: Positive control; Lane 3: Negative control; Lane 4–10: Positive samples.
Antibiogram of E. coli isolated from Kat River and Fort Beaufort abstraction water.
| Antibacterial Agent | Number of Isolates (
| ||
|---|---|---|---|
| Resistant | Intermediate | Susceptible | |
| Ampicillin (AP) | 272 (98%) | 0 (0%) | 6 (2%) |
| Penicillin G (PG) | 278 (100%) | 0 (0%) | 0 (0%) |
| Tetracycline (T) | 37 (13%) | 33 (12%) | 208 (75%) |
| Gentamycin (G) | 0 (0%) | 20 (7%) | 258 (93%) |
| Chloramphenicol (C) | 0 (0%) | 75 (27%) | 203 (73%) |
| Trimethoprim-Sulphamethoxazole (TS) | 105 (38%) | 23 (8%) | 150 (54%) |
| Streptomycin (S) | 22 (8%) | 44 (16%) | 212 (77%) |
| Ciprofloxacin (CIP) | 0 (0%) | 19 (7%) | 259 (93%) |
| Norofloxacin (NOR) | 0 (0%) | 8 (2%) | 272 (98%) |
| Amikacin (AM) | 0 (0%) | 9 (3%) | 269 (97%) |
Incidence of some antibiotic resistance determinants screened.
| Antibiotic Determinant Screened | Resistance Encoded | Number of Isolates Tested | Positives (%) |
|---|---|---|---|
|
| Streptomycin | 22 | 100 |
|
| Tetracycline | 37 | 0 |
|
| β-Lactamase | 272 | 54 |